Sujeet Rajan

Sujeet Rajan

Auto-generated profile, based on publicly available information

Sujeet Rajan

Bombay Hospital Institute of Medical Sciences and Bhatia Hospital, Mumbai, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2022 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
SRSujeet K. Rajan
Sujeet K. Rajan
Vincent CottinVincent Cottin
Vincent Cottin
RDRaja Dhar
Raja Dhar
SDSonye Danoff
Sonye Danoff
KFKevin R. Flaherty
Kevin R. Flaherty
AWAthol U. Wells
Athol U. Wells
This expert group consensus statement emphasises the need for standardising the definition of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis being of paramount importance in ensuring appropriate initial management. Equally, case-by-case decisions on monitoring and management are essential, given the varying presentations of F-ILDs and the varying rates of progression. The value of diagnostic tests in risk stratification at presentation and, separately, the importance of a logical monitoring strategy, tailored to manage the risk of progression, are also stressed. The term “progressive pulmonary fibrosis” (PPF) exactly describes the entity that clinicians often face in practice. The importance of using antifibrotic therapy early in PPF (once initial management has failed to prevent progression) is increasingly supported by evidence. Artificial intelligence software for high-resolution computed tomography analysis, although an exciting tool for the future, awaits validation. Guidance is provided on pulmonary rehabilitation, oxygen and the use of non-invasive ventilation focused specifically on the needs of ILD patients with progressive disease. PPF should be differentiated from acute deterioration due to drug-induced lung toxicity or other forms of acute exacerbations. Referral criteria for a lung transplant are discussed and applied to patient needs in severe diseases where transplantation is not realistic, either due to access limitations or transplantation contraindications. In conclusion, expert group consensus guidance is provided on the diagnosis, treatment and monitoring of F-ILDs with specific focus on the recognition of PPF and the management of pulmonary fibrosis progressing despite initial management.

1 August 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
Vincent CottinVincent Cottin
Vincent Cottin
STSara Tomassetti
Sara Tomassetti
CVClaudia Valenzuela
Claudia Valenzuela
SWSimon L. F. Walsh
Simon L. F. Walsh
KAKaterina M. Antoniou
Katerina M. Antoniou
CRChristopher J. Ryerson
Christopher J. Ryerson
Background: When considering the diagnosis of idiopathic pulmonary fibrosis (IPF), experienced clinicians integrate clinical features that help to differentiate IPF from other fibrosing interstitial lung diseases, thus generating a “pre-test” probability of IPF. The aim of this international working group perspective was to summarize these features using a tabulated approach similar to chest HRCT and histopathologic patterns reported in the international guidelines for the diagnosis of IPF, and to help formally incorporate these clinical likelihoods into diagnostic reasoning to facilitate the diagnosis of IPF. Methods: The committee group identified factors that influence the clinical likelihood of a diagnosis of IPF, which was categorized as a pre-test clinical probability of IPF into “high” (70–100%), “intermediate” (30–70%), or “low” (0–30%). After integration of radiological and histopathological features, the post-test probability of diagnosis was categorized into “definite” (90–100%), “high confidence” (70–89%), “low confidence” (51–69%), or “low” (0–50%) probability of IPF. Findings: A conceptual Bayesian framework was created, integrating the clinical likelihood of IPF (“pre-test probability of IPF”) with the HRCT pattern, the histopathology pattern when available, and/or the pattern of observed disease behavior, into a “post-test probability of IPF.” The diagnostic probability of IPF was expressed using an adapted diagnostic ontology for fibrotic interstitial lung diseases. Interpretation: The present approach will help incorporate the clinical judgment into the diagnosis of IPF, thus facilitating the application of IPF diagnostic guidelines and, ultimately improving diagnostic confidence and reducing the need for invasive diagnostic techniques.

1 January 2020 in Lung India
Verified
Journal Article
Open access
PDF file
SRSujeet Rajan
Sujeet Rajan
NGNithya J Gogtay
Nithya J Gogtay
MKMahanjit Konwar
Mahanjit Konwar
UTUrmila Mukund Thatte
Urmila Mukund Thatte
The Global Initiative for Asthma (GINA) recently released their updated Global Strategy for Asthma Management and Prevention Guide (2019). The pocket guide for practicing clinicians states that “the 2019 GINA strategy report represents the most important change in asthma management in 30 years.” An important recommendation is the change in treatment strategy for the management of mild asthma where the guideline recommends that” all adults and adolescents with asthma should receive either symptom driven (in mild asthma) or daily low dose inhaled corticosteroid (ICS) containing controller treatment to reduce the risk of serious exacerbations.” Our study critically appraises the SYGMA-2 trial, a key trial that largely formed the basis of this recommendation and discusses the potential consequences of using only long-acting beta-2-agonist + ICS as needed as against regular, daily low-dose ICS with as-needed short-acting beta-2-agonist. Our critique covers airway inflammation, disease heterogeneity, understanding the noninferiority margin and its consequences, the Hawthorne effect, and conflict of interest. It is our view that statement of this magnitude will have far-reaching implications for clinical practice which will be in the interests of some patients but also against the interests of others.

1 January 2014 in Lung India
Verified
Journal Article
Open access
PDF file
SRSujeet K Rajan
Sujeet K Rajan
JGJaideepA Gogtay
JaideepA Gogtay
Context: While prescribing an inhaler device, it is important to take into account the usability, preference, confidence, and satisfaction of the patients. Aims: The present study assessed these parameters with Revolizer ® , a novel dry powder inhaler (DPI), in patients with obstructive airway diseases and in device-naïve healthy participants. Settings and Design: In this open-label, prospective, multicentre study with 100 participants [n = 50 healthy participants, n = 45 mild asthma patients, and n = 5 mild chronic obstructive pulmonary disease (COPD) patients], all participants were instructed and trained on the use of Revolizer and then the participants subsequently demonstrated the inhalation technique at two visits. Materials and Methods: The average time required to execute three correct consecutive attempts and the number of errors (including critical errors) were recorded. Participants were asked about the ease of use, preference, confidence, and satisfaction by means of a questionnaire at each visit. Results: The average time required by the participants to achieve three correct consecutive attempts at visit 1 was 3.75 ± 2.10 min, which significantly reduced at visit 2 (3.07 ± 1.32 min, P < 0.01). The number of errors decreased from visit 1 to visit 2. More than 85% participants found the Revolizer easy to use, and it was preferred by more than 75% participants. Revolizer scored high on the confidence and satisfaction of all participants at both visits. Conclusions: Revolizer is an easy-to-use and a preferred device in patients with mild asthma and COPD, as well as in healthy participants with no previous experience of using inhalation devices. The participants felt confident and satisfied using the Revolizer.

11 October 2021
Verified
Book Chapter
Closed access
PDF file
SRSujeet Rajan
Sujeet Rajan
The rapidly increasing popularity of electronic cigarettes (e-cigarettes) has almost reversed 50 years of decreasing use of nicotine among young children and adolescents. The ‘epidemic’ of vaping had begun across the United States and other parts of the developed world. While initially thought to be helpful in preventing the use of combustible cigarette smoking, the effects have possibly been sadly the reverse. The contents of the e-cigarette and other chemicals, including flavouring agents have proven to be far from safe in many respects. The effects on children with asthma and chronic lung disease can well be imagined. So too, can the devastating effects these products have on pregnant women. Far from being a detriment to smoking, these products have actually increased the risk of subsequent consumption of combustible cigarettes and other substance abuse. Preventive measures for youth not yet initiated in e-cigarettes would go a long way. Treatment would largely include behavioural strategies, safer nicotine replacement therapies, and, of course, pharmacotherapy in relevant age groups. This chapter will try and detail the intricate components of e-cigarettes and the harmful effects of smoking and vaping on asthmatics in general.

1 September 2024 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
DCDavid C. Currow
David C. Currow
LSLaure Serresse
Laure Serresse
DJDaisy Janssen
Daisy Janssen
CJChristine Jenkins
Christine Jenkins
MJMiriam J. Johnson
Miriam J. Johnson
TSThomas Similowski
Thomas Similowski